Antioxidant treatment prevents the development of fructose-induced abdominal adipose tissue dysfunction

Clin Sci (Lond). 2013 Jul 1;125(2):87-97. doi: 10.1042/CS20120470.

Abstract

In the present study, we tested the effect of OS (oxidative stress) inhibition in rats fed on an FRD [fructose-rich diet; 10% (w/v) in drinking water] for 3 weeks. Normal adult male rats received a standard CD (commercial diet) or an FRD without or with an inhibitor of NADPH oxidase, APO (apocynin; 5 mM in drinking water; CD-APO and FRD-APO). We thereafter measured plasma OS and metabolic-endocrine markers, AAT (abdominal adipose tissue) mass and cell size, FA (fatty acid) composition (content and release), OS status, LEP (leptin) and IRS (insulin receptor substrate)-1/IRS-2 mRNAs, ROS (reactive oxygen species) production, NADPH oxidase activity and LEP release by isolated AAT adipocytes. FRD-fed rats had larger AAT mass without changes in body weight, and higher plasma levels of TAG (triacylglycerol), FAs, TBARS (thiobarbituric acid-reactive substance) and LEP. Although no significant changes in glucose and insulin plasma levels were observed in these animals, their HOMA-IR (homoeostasis model assessment of insulin resistance) values were significantly higher than those of CD. The AAT from FRD-fed rats had larger adipocytes, higher saturated FA content, higher NADPH oxidase activity, greater ROS production, a distorted FA content/release pattern, lower insulin sensitivity together with higher and lower mRNA content of LEP and IRS-1-/2 respectively, and released a larger amount of LEP. The development of all the clinical, OS, metabolic, endocrine and molecular changes induced by the FRD were significantly prevented by APO co-administration. The fact that APO treatment prevented both changes in NADPH oxidase activity and the development of all the FRD-induced AAT dysfunctions in normal rats strongly suggests that OS plays an important role in the FRD-induced MS (metabolic syndrome) phenotype.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Fat / metabolism*
  • Acetophenones / pharmacology
  • Adipocytes / pathology
  • Animals
  • Antioxidants / pharmacology
  • Biomarkers / blood
  • Body Weight
  • Eating
  • Fatty Acids / metabolism*
  • Fructose / adverse effects*
  • Homeostasis
  • Leptin / blood*
  • Male
  • Metabolic Diseases / chemically induced*
  • Metabolic Diseases / pathology
  • NADPH Oxidases / metabolism
  • Oxidative Stress / drug effects*
  • Rats
  • Rats, Wistar
  • Sweetening Agents / adverse effects*

Substances

  • Acetophenones
  • Antioxidants
  • Biomarkers
  • Fatty Acids
  • Leptin
  • Sweetening Agents
  • Fructose
  • acetovanillone
  • NADPH Oxidases